Clinical trials: Pulmonary Function Tests
Idiopathic Pulmonary Fibrosis
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study.
- Trial name
- NCT06335303
- Testing
- BI 1819479
- Where
- 163 sites in United States, Argentina and 26 more
- Volunteers
- 322 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma
This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale.
- Trial name
- NCT00354666
- Testing
- GSK159797
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.
- Trial name
- NCT02802345
- Testing
- Nintedanib, Sildenafil
- Where
- 85 sites in United States, Australia and 11 more
- Volunteers
- 274 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak…
- Trial name
- NCT03095456
- Testing
- Revefenacin, Spiriva Handihaler®
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Mylan Inc.
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
- Trial name
- NCT02888080
- Testing
- ACZ885
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Targeted Lung Denervation for Patients With Moderate to Severe COPD
The purpose of this study is to evaluate safety of Targeted Lung Denervation (or TLD) in patients suffering from moderate to severe COPD.
- Trial name
- AIRFLOW (NCT02058459)
- Testing
- Holaira™ Lung Denervation System with energy delivery, Holaira™ Lung Denervation System without energy delivery
- Where
- 18 sites in Austria, Belgium and 4 more
- Volunteers
- 128 people
- Sponsor
- Nuvaira, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Effectiveness of the WearME System for COPD Severity and Respiratory Function
This observational study evaluates the effectiveness of the WearME system in monitoring COPD severity and respiratory function by comparing its measurements to standard spirometry, capnography, and other clinical assessments in…
- Trial name
- WearME-COPD (NCT06751537)
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- LASARRUS Clinic and Research Center
Pulmonary Disease, Chronic Obstructive
BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
a 48-week, 2-arm parallel group, "fixed combination" beclomethasone dipropionate plus formoterol fumarate versus formoterol in patients with severe chronic obstructive pulmonary disease
- Trial name
- NCT00929851
- Testing
- CHF1535, Formoterol fumarate
- Where
- United Kingdom
- Volunteers
- 1,199 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Lung Diseases, Interstitial
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study.
- Trial name
- NCT05321082
- Testing
- BI 1015550
- Where
- 400 sites in United States, Argentina and 43 more
- Volunteers
- 1,178 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus
The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with…
- Trial name
- NCT03240575
- Testing
- Tiotropium, Olodaterol, Fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved…
- Trial name
- NCT06502366
- Testing
- BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg
- Where
- 128 sites in United States, China and 4 more
- Volunteers
- 424 people
- Sponsor
- AstraZeneca
Airway Inflammation, Asthma
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
This is a randomised, active-comparator, open-label, parallel-group, multicentre phase IV exploratory study to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA…
- Trial name
- NCT03924635
- Testing
- SYMBICORT and salbutamol
- Where
- 6 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.
Safety and efficacy (measured by spirometry) of UK-432,097 administration will be tested in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00430300
- Testing
- UK-432,097
- Where
- 22 sites in Australia, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Pfizer
Respiratory Disease
Diagnostic Accuracy Of Forced Oscillation Technique To Detect Lung Function Anomalies
The diagnosis of a lung function anomaly requires the evaluation of pulmonary function by spirometry. However, some patients (e.g.
- Trial name
- NCT04006964
- Testing
- Resmon PRO FULL v2
- Where
- 6 sites in United States, Italy
- Volunteers
- 579 people
- Sponsor
- Restech Srl
Idiopathic Pulmonary Fibrosis
Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients
This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months.
- Trial name
- NCT02058602
- Testing
- Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the…
- Trial name
- NCT02371629
- Testing
- NVA237, Salbutamol
- Where
- 81 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 776 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients
The number of people with of asthma and allergy is still increasing and a large number of patients still do not have their asthma well controlled.
- Trial name
- NCT02427165
- Testing
- RPL554, Salbutamol
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 29 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease (COPD)
A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control
The study compared the 24-hour spirometry profile of indacaterol with that of placebo and with tiotropium as an active control in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00615459
- Testing
- Indacaterol, Tiotropium
- Where
- 20 sites in Australia, Germany and 5 more
- Volunteers
- 169 people
- Sponsor
- Novartis
Cystic Fibrosis
A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)
This study is open to adult men with cystic fibrosis and adult women with cystic fibrosis who cannot have children. People with cystic fibrosis can join if they are not eligible to receive cystic fibrosis transmembrane…
- Trial name
- NCT06515002
- Testing
- BI 3720931, Inhaler
- Where
- 5 sites in France, Italy and 3 more
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Cough
Accuracy of Cough Detection in Healthy Adults
Cough is part of the defense mechanism to protect the lung from foreign particles and remove secretions from the airways. However, at times it becomes a bothersome, annoying symptom that interferes with the quality of life, sleep…
- Trial name
- NCT00907491
- Testing
- pulmonary sounds analyzer
- Where
- Israel
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- KarmelSonix Ltd.